Correction of iron deficiency in patients with abnormal uterine bleeding

Abstract

INTRODUCTION: Iron deficiency (ID) occurring latently or as iron deficiency anemia (IDA) is common in gynecology, particularly in patients with abnormal uterine bleeding (AUB).
 AIM: We aimed at exploring the efficiency of a medication containing ferrous sulfate and multivitamins for the correction of latent ID and treatment of mild IDA in AUB patients.
 MATERIALS AND METHODS: We performed a comprehensive clinical, laboratory, and instrumental examination of 60 women aged 35 to 50 years with AUB, revealing many gynecological pathologies (endometrial polyps or hyperplasia, ade nomyosis, and uterine myoma). The examined patients with AUB were divided into two groups: women with latent ID (group 1, n=38) and women with IDA (group 2, n=22). Moreover, all the patients had extragenital pathology in addition to gynecological diseases. As a treatment, ferrous sulfate with multivitamins was prescribed for 13 months.
 RESULTS: Before treatment, the hemoglobin level in the examined patients ranged from 95 to 130 g/L, with an average of 127.11.8 g/L in group 1 and 100.32.1 g/L in group 2. Serum iron concentrations in the examined groups were 9.80.2 and 6.91.3 mol/L, respectively. After treatment, the average levels of hemoglobin and serum iron increased significantly and reached normal levels in all those examined. Hemoglobin was 143.31.8 g/L in group 1 and 122.51.5 g/L in group 2, whereas serum iron was 14.90.2 mol/L in group 1 and 13.51.0 mol/L in group 2. Furthermore, a significant increase to normal values was observed in other indicators of complete blood count and biochemical analysis.
 CONCLUSIONS: The results of the study reveal a high clinical efficiency of ferrous sulfate and multivitamins in the treatment of ID in patients with AUB.

Iron deficiency and ferroptosis in gynecology. Possible corrections: A review of the literature

“…Эффект однократного внутривенного введения препарата выражается в более быстром, по сравнению с приёмом стандартных пер оральных препаратов железа, гемопоэтическом ответе, а также быстром снижении уровня усталости и депрессии, что даёт возможность при определённых обстоятельствах избежать трансфузии эритроцитарной массы. В правильно подобранной дозе препарат может быть введён однократно и пациентам с лёгкой степенью ЖДА, особенно при наличии противопоказаний для перорального приёма железа или необходимости получения быстрого результата лечения, например перед предстоящим хирургическим вмешательством [28,29].…”